Document:

Exhibit 4.1

 

FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON
STOCK

 

Number of Shares: [*]

(subject to adjustment)

 

	Warrant No. [*]	Original Issue Date: September 21, 2022

 

Relmada Therapeutics, Inc., a Nevada corporation
(the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, [HOLDER]. or its registered assigns (the “Holder”), is entitled, subject to the terms set forth
below, to purchase from the Company up to a total of [*] shares of common stock, $0.001 par value per share (the “Common Stock”),
of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at
an exercise price per share equal to $0.001 per share (as adjusted from time to time as provided in Section 9 herein,
the “Exercise Price”), upon surrender of this Warrant to Purchase Common Stock (including any Warrants
to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and
from time to time on or after the date hereof (the “Original Issue Date”), subject to the following terms and conditions:

 

	1.	Definitions. For purposes of this Warrant, the following
terms shall have the following meanings:

 

(a) “Affiliate”
means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, but only for so long as such
control shall continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled
by”, “controlling” and “under common control with”) means, with respect to a Person, possession, direct
or indirect, of (a) the power to direct or cause direction of the management and policies of such Person (whether through ownership
of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities
(whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.

 

(b) “Commission”
means the United States Securities and Exchange Commission.

 

(c) “Closing
Sale Price” means, for any security as of any date, the last trade price for such security on the Principal Trading Market for
such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours
basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time,
as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the over-the-counter
market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot
be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date
shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree
upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine
the fair market value. The Board of Directors’ determination shall be binding upon all parties absent demonstrable error. All such
determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during
the applicable calculation period.

 

(d) “Principal
Trading Market” means the national securities exchange or other trading market on which the Common Stock is primarily listed
on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market.

 

(e) “Securities
Act” means the Securities Act of 1933, as amended.

 

(f) “Trading
Day” means any weekday on which the Principal Trading Market is normally open for trading.

 

(g) “Transfer
Agent” means Empire Stock Transfer Inc., the Company’s transfer agent
and registrar for the Common Stock, and any successor appointed in such capacity.

 

     

     

    

 

	2.	Registration of Warrants. The Company shall register
ownership of this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”),
in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant
is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner
hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to
the contrary.

 

	3.	Registration of Transfers. Subject to compliance with
all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of
this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any
such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant,
a “New Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New
Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The
acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations
in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to,
prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 3. Until due presentment
for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company
shall not be affected by any notice to the contrary.

 

	4.	Exercise and Duration of Warrants.

 

(a) All or any
part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to
time on or after the Original Issue Date.

 

(b) The Holder
may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto
(the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant
Shares as to which this Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the
Exercise Notice pursuant to Section 10 below), and the date on which the last of such items is delivered to the
Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not
be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall
have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining
number of Warrant Shares, if any. The aggregate exercise price of this Warrant, except for the Exercise Price, was pre-funded to the Company
on or before the Original Issue Date, and consequently no additional consideration (other than the Exercise Price) shall be required by
to be paid by the Holder to effect any exercise of this Warrant.  The Holder shall not be entitled to the return or refund of
all, or any portion, of such pre-funded exercise price under any circumstance or for any reason whatsoever.

 

	5.	Delivery of Warrant Shares.

 

(a) Upon exercise
of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), (i) provided
that the Company’s Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities
Transfer Program (the “FAST Program”), upon the request of the Holder, credit such aggregate number of shares of Common
Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with The
Depository Trust Company (“DTC”) through its Deposit Withdrawal at Custodian (DWAC) system, or if the Transfer Agent
is not participating in the Fast Program, issue and dispatch by overnight courier to the address as specified in the Exercise Notice,
a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of Warrant Shares
to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a “Person”)
so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of
the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or a certificate therefor
is issued, as the case may be.

 

    2

     

    

 

(b) If by the
close of the third (3rd) Trading Day after the Exercise Date, the Company fails to issue and dispatch to the Holder a certificate
representing the required number of Warrant Shares in the manner required pursuant to Section 5(a) or fails to credit
the Holder’s balance account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such third
(3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise)
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving
upon such exercise (a “Buy-In”), then the Company shall, within three (3) Trading Days after the Holder’s
request and in the Holder’s sole discretion, either (1) pay in cash to the Holder an amount equal to the Holder’s total
purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company’s
obligation to deliver such certificate or credit such account (and to issue such Warrant Shares) shall terminate or (2) promptly
honor its obligation to deliver to the Holder such Warrant Shares in the manner provided in Section 5(a) and pay cash
to the Holder in an amount equal to the excess (if any) of Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased in the Buy-In over the product of (A) the number of shares of Common Stock purchased
in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.

 

(c) To the extent
permitted by law and subject to Section 5(b), the Company’s obligations to issue and deliver Warrant Shares in accordance with
and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional,
irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation
or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such
obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein
shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

	6.	Charges, Taxes and Expenses. Issuance and delivery
of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or
transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance
of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall
not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant
Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other
tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

 

	7.	Replacement of Warrant. If this Warrant is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof,
or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested
by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures
and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation
of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s
obligation to issue the New Warrant.

 

	8.	Reservation of Warrant Shares. The Company covenants
that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free
from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments
and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon
issuance and the payment of the applicable Exercise Price (including by means of a “cashless exercise under Section 10 below) in
accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all
such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common
Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions
to increase the par value of the Common Stock at any time while this Warrant is outstanding.

 

    3

     

    

 

	9.	Certain Adjustments. The Exercise Price and number
of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

 

(a) Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common
Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance
with the terms of such stock on the Original Issue Date or as amended, that is payable in shares of Common Stock, (ii) subdivides
its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common
Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional
shares of Common Stock of the Company, then in each such case the Exercise Price shall be adjusted to equal the product of the Exercise
Price multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such
event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event (provided,
however, that in no event shall the Exercise Price be adjusted to be less than the par value per share of the Common Stock), and
the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately,. Any
adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and
such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business
on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of
such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective
date of such subdivision or combination.

 

(b) Pro
Rata Distributions. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for
no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by
the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset
(in each case, “Distributed Property”), then, upon any exercise of this Warrant that occurs after the record date fixed
for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant
Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive
in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record
date without regard to any limitation on exercise contained therein.

 

(c) Fundamental
Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company
with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately
prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately
after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets
in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company
or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the
Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme
of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the
Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially
the same proportions, the voting power of such Person immediately after the transaction), or (v) the Company effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above)
(in any such case, a “Fundamental Transaction”), then upon such Fundamental Transaction the Holder shall have the right
to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to
receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder
of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained
herein (the “Alternate Consideration”). The Company shall not effect any Fundamental Transaction in which the Company
is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration
is solely cash and the Company provides for the simultaneous “cashless exercise” of this Warrant pursuant to Section 10 below
or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including
any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance
with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant.  The provisions
of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type.

 

    4

     

    

 

(d) Calculations.
All calculations under this Section 9 shall be made to the nearest one-tenth of one cent or the nearest share, as
applicable.

 

(f) Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will,
at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and
prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type
of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise
to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly
deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 

(g) Notice
of Corporate Events. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of
cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to
subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement
contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation
or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material
non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the
applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect
to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the
validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company
authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated
by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), the Company shall
deliver to the Holder a notice of such Fundamental Transaction at least thirty (30) days prior to the date such Fundamental Transaction
is consummated. Holder agrees to maintain any information disclosed pursuant to this Section 9(g) in confidence until such information
is publicly available, and shall comply with applicable law with respect to trading in the Company’s securities following receipt
any such information.

 

	10.	Payment of Exercise Price. Notwithstanding anything
contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a
“cashless exercise”, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of
securities effected pursuant to Section 3(a)(9) of the Securities Act, as determined as follows:

 

X = Y [(A-B)/A]

 

where:

 

“X” equals
the number of Warrant Shares to be issued to the Holder;

 

“Y” equals
the total number of Warrant Shares with respect to which this Warrant is then being exercised;

 

“A” equals the Closing Sale
Price of the shares of Common Stock (as reported by Bloomberg Financial Markets) as of the Trading Day on the date immediately preceding
the Exercise Date; and

 

“B” equals the Exercise
Price then in effect for the applicable Warrant Shares at the time of such exercise.

 

Except as set forth in Section 5(b)
(Buy-In remedy) and Section 12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled
in cash.

 

    5

     

    

 

	11.	Limitations on Exercise.

 

(a) Notwithstanding
anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled
to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately
prior to such exercise, would result in (i) the aggregate number of shares of Common Stock beneficially owned by the Holder
and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes
of Section 13(d) of the Exchange Act, to exceed 9.99% (the “Maximum Percentage”) of the total number
of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the
securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common
Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to exceed the Maximum Percentage of
the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant,
in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock
as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to
the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer
agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within
three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common
Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to
any other percentage specified in such notice not in excess of 19.99%; provided that any such increase will not be effective
until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate
number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose
beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act
shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised
and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled
portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company
which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right,
option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein
and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act.

 

(b) This Section 11 shall
not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities
or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of
this Warrant.

 

	12.	No Fractional Shares. No fractional Warrant Shares
will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the
number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the
fair market value (based on the Closing Sale Price) for any such fractional shares.

 

    6

     

    

 

	13.	Notices. Any and all notices or other communications
or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective
on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail
at the facsimile number or e-mail address specified in the books and records of the Transfer Agent prior to 5:30 P.M., New York City
time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via
facsimile or confirmed e-mail at the facsimile number or e-mail address specified in the books and records of the Transfer Agent on a
day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the
date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon
actual receipt by the Person to whom such notice is required to be given, if by hand delivery.

 

If to the Company:

 

Relmada Therapeutics, Inc.

2222 Ponce de Leon, Floor 3

Coral Gables, FL 33134

Email: cence@relmada.com

 

	14.	Warrant Agent. The Company shall initially serve as
warrant agent under this Warrant. Upon thirty (30) days’ notice to the Holder, the Company may appoint a new warrant agent.
Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to
which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers
substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without
any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first
class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

 

	15.	Miscellaneous.

 

(a) No
Rights as a Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to
vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights
of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue
of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.

 

(b) Authorized
Shares.

 

(i) Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (c) use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

 

    7

     

    

 

(ii) Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof.

 

(c) Successors
and Assigns. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not
be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction.
This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject
to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any
legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company
and the Holder, or their successors and assigns.

 

(d) Amendment
and Waiver. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent
of the Holder.

 

(e) Acceptance.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

(f) Governing
Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED
BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION
CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY
WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF
ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING
SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE
OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

 

(g) Headings.
The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.

 

(h) Severability.
In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder
will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    8

     

    

 

IN WITNESS WHEREOF, the Company has caused this
Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	RELMADA THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	Name: 	Maged Shenouda
	 	Title:	Chief Financial Officer

 

[Signature Page to Pre-Funded Warrant No. 1]

 

    9

     

    

 

SCHEDULE 1

 

FORM OF EXERCISE NOTICE

 

[To be executed by the Holder to purchase shares
of Common Stock under the Warrant]

 

Ladies and Gentlemen:

 

		(1)	The undersigned is the Holder of Warrant No. __ (the “Warrant”) issued by Relmada Therapeutics, Inc., a Nevada
corporation (the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings
set forth in the Warrant.

 

		(2)	The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant by “cashless exercise” under
Section 10 of the Warrant.

 

		(3)	Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of
the Warrant.

 

		(4)	By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise
evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with
Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of
the Warrant to which this notice relates.

 

	Dated:	 	 
	 	 	 
	Name of Holder:	 	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	 	 

 

(Signature must conform in all respects to name of Holder as specified
on the face of the Warrant)

 

 

10Exhibit
10.1

 

September
21, 2022

 

Relmada
Therapeutics, Inc.

2222 Ponce de Leon, Floor 3

Coral Gables, FL 33134

 

		Re:	Section
                                            3(a)(9) Exchange Agreement

 

Ladies
and Gentlemen:

 

This
letter agreement (the “Agreement”) confirms the agreement of Relmada Therapeutics, Inc., a Nevada corporation
(the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”),
pursuant to which the Stockholders have agreed to exchange an aggregate of 1,452,016 shares (the “Shares”)
of Common Stock, par value $0.001 per share (the “Common Stock”), beneficially owned by the Stockholders in
consideration for one or more Common Stock purchase warrants in the form attached hereto as Exhibit A (each a “Warrant”)
to purchase an aggregate of 1,452,016 shares of Common Stock (the “Warrant Shares”) on the terms specified
below.

 

In
consideration of the foregoing, the Company and the Stockholders agree as follows:

 

(1) No
later than the close of business on the first day after the date hereof on which The Nasdaq Stock Market is open for trading (a “Trading
Day”), or such other date as mutually agreed upon by the parties of this Agreement (the “Closing Date”),
and subject to the satisfaction or waiver of the conditions set forth herein, the Stockholders shall exchange the Shares for the Warrants
(the “Exchange”) in the respective amounts listed on Schedule I. The Exchange shall be consummated pursuant
to Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). On or prior to the Closing
Date: (a) the Stockholders shall jointly and irrevocably instruct their broker to transfer the Shares through the Deposit Withdrawal
at Custodian (“DWAC”) system to Empire Stock Transfer Inc. (the “Transfer Agent”);
(b) the Company and the Stockholders shall jointly and irrevocably instruct the Transfer Agent to take such Shares and register them
in the name of the Company; and (c) the Company shall issue and deliver to the Stockholders the Warrants exercisable for the Warrant
Shares, in the amounts and in the names set forth on Schedule I and shall instruct the Transfer Agent to reserve 1,452,016 shares
of Common Stock, issuable upon the exercise of the Warrants.

 

(2)
The Company represents and warrants to each Stockholder as follows:

 

(a) Neither
the Company nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given,
or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of the
Securities Act and the rules and regulations of the Commission promulgated thereunder) for soliciting the Exchange. Assuming the representations
and warranties of the Stockholders contained herein are true and complete, the Exchange will qualify for the registration exemption contained
in Section 3(a)(9) of the Securities Act.

 

(b) It
has the requisite corporate power and authority and power to enter into this Agreement and to consummate the Exchange, and such transactions
shall not contravene any contractual, regulatory, statutory or other obligation or restriction applicable to the Company.

 

(c) It
has reserved a sufficient number of shares of Common Stock as may be necessary to fully permit the exercise of the Warrants as of the
date of issuance and the issuance of the Warrant Shares, without regard to any adjustment provisions or beneficial ownership limits set
forth in the Warrant.

 

     

     

    

 

(3)
Each Stockholder, as to itself only, represents and warrants to the Company as follows:

 

(a) It
has the requisite power and authority to enter into this Agreement and consummate the Exchange and such transactions will not contravene
any contractual, regulatory, statutory or other obligation or restriction applicable to such Stockholder.

 

(b) It
is the record and beneficial owner of, and has valid and marketable title to, the Shares being exchanged by it pursuant to this Agreement,
free and clear of any lien, pledge, restriction or other encumbrance (other than restrictions arising pursuant to applicable securities
laws), and has the absolute and unrestricted right, power and capacity to surrender and exchange the Shares being exchanged by it pursuant
to this Agreement, free and clear of any lien, pledge, restriction or other encumbrance. It is not a party to or bound by, and the Shares
being exchanged by it pursuant to this Agreement are not subject to, any agreement, understanding or other arrangement (i) granting any
option, warrant or right of first refusal with respect to such Shares to any person, (ii) restricting its right to surrender and exchange
such Shares as contemplated by this Agreement, or (iii) restricting any other of its rights with respect to such Shares, and the Stockholders
have received no additional consideration for the Shares other than Pre-funded Warrants.

 

(c) Neither
it nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid or given, or agreed
to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) and the rules and
regulations of the Commission promulgated thereunder) for soliciting the Exchange.

 

(4) This
agreement, and any action or proceeding arising out of or relating to this agreement, shall be exclusively governed by the laws of the
State of New York.

 

(5) In
the event that any part of this agreement is declared by any court or other judicial or administrative body to be null, void or unenforceable,
said provision shall survive to the extent it is not so declared, and all of the other provisions of this agreement shall remain in full
force and effect. In such an event, the Stockholders and the Company shall endeavor in good faith negotiations to modify this agreement
so as to affect the original intent of the parties as closely as possible.

 

(6) This
Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together,
shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and
delivered to the other parties. Each of the undersigned parties hereto acknowledge and agree that this Agreement may be executed by electronic
signature, which shall have the same legal force and effect as a handwritten signature.

 

[SIGNATURE
PAGE FOLLOWS]

 

    2

     

    

 

Please
sign to acknowledge agreement with the above terms and return to the undersigned.

 

	 	Common Stockholder:
	 	 	 
	 	Venrock Healthcare Capital Partners EG, L.P.
	 	By:	VHCP Management EG, LLC, its general partner
	 	 	 
	 	By:	/s/ Nimish Shah
	 	Name:	Nimish Shah
	 	Title:	Authorized Signatory
	 	 	 
	 	Venrock Healthcare Capital Partners
    II, L.P.
	 	By:	VHCP Management II, LLC, its general partner
	 	By:	VR Advisor, LLC, its manager
	 	 	 
	 	By:	/s/ Nimish Shah
	 	Name: 	Nimish Shah
	 	Title:	Authorized Signatory
	 	 	 
	 	VHCP Co-Investment Holdings II, LLC
	 	By:	VHCP Management II, LLC, its general partner
	 	By:	VR Advisor, LLC, its manager
	 	 	 
	 	By:	/s/ Nimish Shah
	 	Name:	Nimish Shah
	 	Title:	Authorized Signatory
	 	 	 
	 	Venrock Healthcare Capital Partners
    III, L.P.
	 	By:	VHCP Management III, LLC, its general partner
	 	By:	VR Advisor, LLC, its manager
	 	 	 
	 	By:	/s/ Nimish Shah
	 	Name:	Nimish Shah
	 	Title:	Authorized Signatory
	 	 	 
	 	VHCP Co-Investment Holdings III, LLC
	 	By:	VHCP Management III, LLC, its manager
	 	By:	VR Advisor, LLC, its manager
	 	 	 
	 	By:	/s/ Nimish Shah
	 	Name:	Nimish Shah
	 	Title:	Authorized Signatory

 

Signature
Page to Warrant Exchange Agreement

 

    3

     

    

 

	 	Acknowledged and agreed to:
	 	 	 
	 	Relmada Therapeutics, Inc.
	 	 	 
	 	By:	/s/ Maged Shenouda
	 	Name: 	Maged Shenouda
	 	Title:	Chief Financial Officer

 

Signature
Page to Warrant Exchange Agreement

 

    4

     

    

 

SCHEDULE
I 

 

	Exchanging Stockholder	 	Shares to be

Exchange	 	 	Warrant

Shares	 
	Venrock Healthcare Capital Partners EG, L.P.	 	 	590,912	 	 	 	590,912	 
	Venrock Healthcare Capital Partners II, L.P.	 	 	174,214	 	 	 	174,214	 
	VHCP Co-Investment Holdings II, LLC	 	 	70,620	 	 	 	70,620	 
	Venrock Healthcare Capital Partners III, L.P.	 	 	560,238	 	 	 	560,238	 
	VHCP Co-Investment Holdings III, LLC	 	 	56,032	 	 	 	56,032	 

 

     

     

    

 

EXHIBIT
A

 

FORM
OF WARRANT TO PURCHASE COMMON STOCK

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]